Skip to content

CASSIPHARMA

Active Private limited company (pre-2019)founded 2002active for 24 yearsKoning Boudewijnstraat 25, 9000 GhentKBO/BCE: BE 0477.736.777 subsidiary of

Lifetime

19 annual accounts with figures on one time axis, 23 filings since 2003
peak of €387,780 in 2011
€167,759▲ 26.6%
lowest -€71,001 in 2023
€8,177▲ €23,675
peak of €1.0m in 2013
€217,796▲ 0.4%
€331,191▼ 2.3%
peak of 4.9 FTE in 2011
2.1 FTEunchanged
Board2 names since 2014
1 director
Owners
99%
Documentsfilings and deeds
30-01-20261 day before the deadline
2025abbreviated format
Gross margin from €132,499 to €167,759Profit of €8,177, after a loss

Key points

from the 2025 annual accounts

Equity

€217,796 from €1.0m in 2013

Equity fell by 79% in 12 years.

Turnover

≈ €790,000 estimated

The abbreviated format states no turnover.

Filings

23 annual accounts since 2003
deadline20102020

The last five annual accounts were filed 0 to 12 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,047 companies had the same profile as CASSIPHARMA has now. Each dot stands for 43 companies, two years later.

94.3%
were still trading
5.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,047 companies, not a prediction for CASSIPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director,
  • 99%equity €2.8m (2025) · annual accounts 30-06-2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0477736777
Demerger: CASSIPHARMA splits off to DOMICAPHARMA changes role from manager to director · acts as permanent representative · “nieuw voorwerp” (deed in Dutch) · General meeting of 30-01-2023 · Gazette deed
Demerger proposal: CASSIPHARMA splits off to DOMICAPHARMA appointed as statutory auditor · and act as permanent representatives · Gazette deed
New manager appointed, resigned · acts as permanent representative · Director discharge: · General meeting of 27-01-2014 · Gazette deed
All 34 events

Comparable companies

same main activity, similar in size and age
Company
CASSIPHARMA Ghent €548,988 €167,759 39.7% 2.1
PHARMACIE FILECCIA Soignies €510,979 €168,957 87.1% 2
APOTHEEK NAUWELAERTS Heist-op-den-Berg €589,466 €184,494 32.5% 2.2
PHARMACIE DEMEULDRE - DEGIVE Esneux €604,841 €172,114 29.1% 1.9
APOTHEEK VAN OVERBERGE - VAN DEN STEEN Ghent €536,689 €179,437 16.1% 1.8
VERZELE PHARMA Oudenaarde €500,597 €186,426 33.2% 2
Apotheek De Groot Kris Westerlo €527,086 €187,069 7.4% 2.2

These companies have the same main activity as CASSIPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €501,000 and €605,000, founded between 1996 and 2008.

Official details

Source: KBO
Status
Active since 12-06-2002Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 30-06-2025
Establishment unit
2.096.297.5839000 Ghent, since 14-08-2002
Financial year end
30 June
Peppol
Reachable since 07-10-2025
Company details

Annual accounts to 30-06-2025

€548,988▼ 1.3%
Employeeson 30-06-2025
3=
Filing
Filed on 30-01-2026, 1 day before the end of the filing period
Financials

Insights on CASSIPHARMA

CASSIPHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €285,099 in 2007 to €167,759 in 2025.

holds 99% of the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about CASSIPHARMA

What is the company number of CASSIPHARMA?
The company number of CASSIPHARMA is 0477.736.777. The VAT number is the same number with BE in front: BE 0477.736.777.
Where is CASSIPHARMA based?
The registered office is at Koning Boudewijnstraat 25, 9000 Ghent.Company details
What does CASSIPHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of CASSIPHARMA?
CASSIPHARMA is a private limited company (pre-2019) (BVBA).
When was CASSIPHARMA founded?
CASSIPHARMA was founded on 12-06-2002.
Is CASSIPHARMA still active?
Yes, CASSIPHARMA is an active enterprise in the KBO register.
How many employees does CASSIPHARMA have?
CASSIPHARMA had an average of 2.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does CASSIPHARMA fall under?
In its 30-06-2025 annual accounts, CASSIPHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of CASSIPHARMA?
The turnover in financial year 2025 is ≈ €790,000. This figure is estimated from the gross margin of €167,759 and 43 comparable companies (NACE 477). It probably lies between €520,000 and €1.7m.
Is CASSIPHARMA profitable?
In financial year 2025, CASSIPHARMA made a profit of €8,177.
Where can I find the annual accounts of CASSIPHARMA?
CASSIPHARMA filed 23 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of CASSIPHARMA due?
CASSIPHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.